153 related articles for article (PubMed ID: 28251282)
21. Gemcitabine plus S-1 for metastatic pancreatic cancer.
Zhu H; Yi C; Zhao Y; Gou H
Medicine (Baltimore); 2018 Oct; 97(41):e12836. PubMed ID: 30313120
[TBL] [Abstract][Full Text] [Related]
22. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
[TBL] [Abstract][Full Text] [Related]
23. Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).
Schultheis B; Strumberg D; Bergmann L; Graeven U; Hanauske AR; Lipp R; Schuette J; Saito K; Scigalla P; Scheulen ME
Invest New Drugs; 2012 Jun; 30(3):1184-92. PubMed ID: 21484249
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.
Shinchi H; Maemura K; Mataki Y; Kurahara H; Sakoda M; Ueno S; Hiraki Y; Nakajo M; Natsugoe S; Takao S
J Hepatobiliary Pancreat Sci; 2012 Mar; 19(2):152-8. PubMed ID: 21647560
[TBL] [Abstract][Full Text] [Related]
25. Final results of a phase II study of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma.
Naito S; Tatsugami K; Shinohara N; Tomita Y; Mizokami A; Fujisawa M; Hashine K; Nishikido M; Nakagawa M; Tsukamoto T; Akaza H
Jpn J Clin Oncol; 2014 Feb; 44(2):122-6. PubMed ID: 24298041
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Shirai Y; Nakagawa A; Kawakami H; Uno T; Ito H; Saisho H
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):219-24. PubMed ID: 17189072
[TBL] [Abstract][Full Text] [Related]
27. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
[TBL] [Abstract][Full Text] [Related]
28. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
[TBL] [Abstract][Full Text] [Related]
29. Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial.
Yoshimura K; Uehara K; Tojima Y; Kawai S; Mokuno Y; Maeda A; Kyokane T; Kobayashi S; Yoshioka Y; Nagino M
Trials; 2013 Jan; 14():17. PubMed ID: 23320901
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
Takashima A; Morizane C; Ishii H; Nakamura K; Fukuda H; Okusaka T; Furuse J
Jpn J Clin Oncol; 2010 Dec; 40(12):1189-91. PubMed ID: 20630899
[TBL] [Abstract][Full Text] [Related]
31. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
[TBL] [Abstract][Full Text] [Related]
32. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.
Zhang W; Du C; Sun Y; Yang L; Cui C; Jiang Z; Wang C; Wang J; Zhou A
Cancer Chemother Pharmacol; 2018 Oct; 82(4):655-660. PubMed ID: 30054709
[TBL] [Abstract][Full Text] [Related]
33. S-1 in the treatment of pancreatic cancer.
Sudo K; Nakamura K; Yamaguchi T
World J Gastroenterol; 2014 Nov; 20(41):15110-8. PubMed ID: 25386059
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
Uwagawa T; Sakamoto T; Abe K; Okui N; Hata D; Shiba H; Futagawa Y; Aiba K; Yanaga K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):191-6. PubMed ID: 25422155
[TBL] [Abstract][Full Text] [Related]
35. Outpatient oral chemotherapy with S-1 for unresectable or distant metastatic head and neck cancer.
Maeda M; Yamashita T; Matsunobu T; Araki K; Tomifuji M; Shiotani A
Anticancer Res; 2013 Aug; 33(8):3285-9. PubMed ID: 23898093
[TBL] [Abstract][Full Text] [Related]
36. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
Narahara H; Iishi H; Imamura H; Tsuburaya A; Chin K; Imamoto H; Esaki T; Furukawa H; Hamada C; Sakata Y
Gastric Cancer; 2011 Mar; 14(1):72-80. PubMed ID: 21340666
[TBL] [Abstract][Full Text] [Related]
38. A late phase II study of S-1 for metastatic pancreatic cancer.
Okusaka T; Funakoshi A; Furuse J; Boku N; Yamao K; Ohkawa S; Saito H
Cancer Chemother Pharmacol; 2008 Apr; 61(4):615-21. PubMed ID: 17520253
[TBL] [Abstract][Full Text] [Related]
39. Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Okamoto K; Otsuji E; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Yamashita T; Taniguchi F; Aragane H; Nishi H; Itokawa Y; Morita S; Sakamoto J
Gastric Cancer; 2010 Aug; 13(3):149-54. PubMed ID: 20820983
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
Sudo K; Yamaguchi T; Nakamura K; Denda T; Hara T; Ishihara T; Yokosuka O
Cancer Chemother Pharmacol; 2011 Feb; 67(2):249-54. PubMed ID: 20352216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
